Browsing Tag
cell therapy
24 posts
Why NCEL-101’s FDA pathway could influence the future of stem-cell-derived islet therapies
Why NewcelX Ltd.’s FDA pre-IND process for NCEL-101 could shape the future of regenerative diabetes medicine. Read the full analysis.
JW Therapeutics says China pharma deals remain insulated from Beijing’s sensitive technology scrutiny
JW Therapeutics says China pharma deals remain open despite Beijing tech scrutiny. See why biotech licensing still matters.
Can Fujifilm’s Madison iPSC facility turn stem cell science into scalable manufacturing?
iPSC demand is rising fast. Fujifilm’s Madison expansion tests whether stem cell manufacturing can keep pace with drug discovery and therapy scale-up.
Can in vivo CAR T therapies expand access beyond specialized treatment centers
Explore how CPTx’s in vivo CAR T strategy could lower costs, simplify delivery, and expand access beyond specialized cancer treatment centers.
What rezanecel’s durability data means for epilepsy treatment innovation
Neurona Therapeutics’ rezanecel shows durable seizure reduction. Discover what this means for epilepsy treatment innovation and future market dynamics.
Cynata Therapeutics (ASX: CYP) completes Phase 2 enrolment for CYP-001 as investors refocus on June 2026 data inflection
Cynata Therapeutics completes Phase 2 enrolment for CYP-001, shifting focus to June 2026 data. Read what this means for strategy, risk, and valuation.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Biorep achieves first successful independent PRISM system use in islet isolation
Biorep’s PRISM system achieves first independent islet isolation milestone at SNBTS. Discover how it’s shaping the future of lab automation.
Will Enlivex’s macrophage therapy redefine osteoarthritis care in seniors?
Enlivex posts 6-month knee osteoarthritis trial success with Allocetra, signaling a new era in age-targeted cell therapy. See what comes next.
Breakthrough allogeneic immunotherapy from Lunai Bioworks eliminates pancreatic tumors in preclinical study
Find out how Lunai Bioworks’ engineered dendritic-cell therapy achieved complete regression of pancreatic cancer in preclinical models and what it means for solid-tumor immunotherapy.